The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2021 | Onvansertib for second-line treatment of KRAS-mutated mCRC
Heinz-Josef Lenz, MD, FACP, University of Southern California, Los Angeles, CA, highlights the progress in developing agents targeting the MAP-kinase signaling pathway, including the development of onvasertinib, a polo-like kinase 1 inhibitor currently evaluated in a Phase Ib/II study in combination with FOLFIRI and bevacizumab in patients with KRAS-mutated metastatic colorectal cancer (mCRC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
